Summary
Abstract
Infliximab is a chimeric monoclonal antibody that binds to tumour necrosis factor-α (TNFα) and neutralises its effects. TNFα plays an important role in the development of both Crohn’s disease and rheumatoid arthritis.
In a large, double-blind, randomised study involving patients with active, refractory Crohn’s disease, significantly more recipients of intravenous infliximab, compared with placebo, achieved a clinical response after 4 weeks’ follow-up. Moreover, infliximab administration was associated with a rapid improvement in endoscopic and histological findings in clinical trials involving patients with active, refractory Crohn’s disease. The results of the A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT) I study showed that maintenance infliximab therapy prolonged response and remission in patients with moderate to severe Crohn’s disease.
In patients with enterocutaneous fistulae associated with Crohn’s disease who were involved in a double-blind, randomised study, significantly more patients who received multiple infusions of infliximab, compared with placebo, experienced a ≥50% reduction from baseline in the number of draining fistulae at ≥2 consecutive study visits.
In patients with active rheumatoid arthritis refractory to treatment with methotrexate who were enrolled in a large, double-blind, randomised study [the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) study], American College of Rheumatology (ACR) 20, 50 and 70% response rates were seen in significantly more patients who received multiple infusions of infliximab plus methotrexate, compared with methotrexate plus placebo, after 30 and 54 weeks’ treatment. Moreover, the ACR 20% response rate was maintained after 102 weeks’ treatment. In addition, significantly less radiographic progression was seen in infliximab plus methotrexate, compared with methotrexate plus placebo, recipients after 54 weeks’ treatment.
Infliximab therapy was also associated with improvements in health-related quality of life in patients with Crohn’s disease or rheumatoid arthritis.
Infliximab was generally well tolerated in clinical trials with the most common adverse events including upper respiratory tract infection, headache, nausea, coughing, sinusitis and diarrhoea. Infliximab therapy may be associated with an increased risk of reactivation of tuberculosis in patients with latent disease.
In conclusion, infliximab is an important treatment option in patients with active Crohn’s disease who have not responded to conventional therapy and in patients with Crohn’s disease who have fistulae. Moreover, infliximab plus methotrexate is effective in patients with active rheumatoid arthritis who have not responded adequately to traditional disease-modifying antirheumatic drugs, in terms of reducing symptoms and signs, improving physical function and delaying the progression of structural damage.
Pharmacodynamic Properties
Tumour necrosis factor-α (TNFα) plays an important role in the development of both Crohn’s disease and rheumatoid arthritis. Infliximab is a chimeric monoclonal antibody against TNFα. Administration of infliximab reduced the expression of proinflammatory cytokines and chemokines in biopsy samples from patients with Crohn’s disease [e.g. TNFα, interferon-γ, monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory protein-2 and regulated upon activation, normal T cell expressed and secreted] or rheumatoid arthritis [TNFα, interleukin (IL)-8 and MCP-1]. Levels of proinflammatory cytokines and chemokines in the sera of patients with Crohn’s disease (e.g. IL-6) or rheumatoid arthritis (e.g. IL-6 and IL-1β) were also reduced.
Infliximab therapy also reduced the expression of endothelial adhesion molecules in biopsy samples from patients with Crohn’s disease [intercellular adhesion molecule-1 (ICAM-1)] or rheumatoid arthritis (E-selectin and vascular cell adhesion molecule-1). Levels of endothelial adhesion molecule were also reduced in the sera of patients with Crohn’s disease (ICAM-1) or rheumatoid arthritis (E-selectin and ICAM-1). This reduction in endothelial adhesion molecule expression is potentially responsible, in part, for the reduced influx of leucocytes into the gut mucosa of patients with Crohn’s disease who received infliximab and the reduced movement of granulocytes into the joints of patients with rheumatoid arthritis who received infliximab.
Transient increases in peripheral blood lymphocyte counts were commonly seen after administration of infliximab to patients with Crohn’s disease or rheumatoid arthritis. Changes in peripheral blood monocyte and neutrophil counts were also seen following infliximab administration; these were usually of transient duration.
Infliximab administration was also associated with reductions in serum levels of several other factors implicated in the pathogenesis of Crohn’s disease (phospholipase A2) or rheumatoid arthritis (matrix metalloproteinase-1 and -3, vascular endothelial growth factor), as well as reductions in nitric oxide synthase type 2 protein expression and nitric oxide synthase activity in patients with rheumatoid arthritis.
Pharmacokinetic Properties
Dose-dependent increases in maximum plasma concentration (192.1, 426.7 and 907.4 mg/L, respectively) and in the area under the concentration-time curve (49 909, 78 178 and 173 043 mg · h/L, respectively) were seen with administration of single intravenous infusions of infliximab 5, 10 or 20 mg/kg to patients with rheumatoid arthritis. Most of these patients still had detectable serum infliximab concentrations 10 weeks after treatment. In patients with rheumatoid arthritis, serum infliximab concentrations appeared to be sustained for longer with concomitant administration of methotrexate. Patients with Crohn’s disease who received multiple infliximab infusions had stable serum concentrations 8 weeks after each infusion; most patients had detectable serum infliximab concentrations 12 weeks after the last dose.
Administration of single intravenous infusions of infliximab 5, 10 or 20 mg/kg to patients with rheumatoid arthritis showed that the volume of distribution of infliximab is independent of dose (3.1 to 4.3L) [suggesting mainly intravascular distribution], as is the clearance (approximately 0.011 L/h) and the terminal elimination half-life (215 to 295 hours).
Clinical Efficacy
In Crohn’s Disease
In clinical trials, single infusions of intravenous infliximab 5 to 20 mg/kg were associated with a clinical response [defined as a reduction in the Crohn’s Disease Activity Index (CDAI) of ≥70 or >70 points] in 50 to 81% of patients with active, refractory Crohn’s disease after 4 weeks’ follow-up. In addition, after 4 weeks’ follow-up, remission (defined as a CDAI score of <150) had occurred in 20 to 75% of infliximab recipients. In a large, double-blind, randomised, 12-week trial, in which 108 patients with active, refractory Crohn’s disease received single infusions of intravenous infliximab 5, 10 or 20 mg/kg, significantly greater reductions from baseline in CDAI scores were seen in infliximab than placebo recipients 2 and 4 weeks’ after treatment, indicating rapid symptomatic improvement.
The results of the A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen (ACCENT) I study, involving 573 patients, showed that maintenance infliximab therapy prolonged response and remission in patients with moderate to severe Crohn’s disease. Significantly more recipients of infliximab 5 or 10 mg/kg, compared with placebo, demonstrated a clinical response (51.3 and 59.1 vs 27.3%), or were in clinical remission (38.9 and 45.5 vs 21.9%), after 30 weeks’ follow-up. Moreover, additional analyses of ACCENT I showed that infliximab therapy had a corticosteroid-sparing effect and that regular maintenance therapy was more effective than episodic on-demand treatment with regards to clinical response and remission rates.
Clinical trials involving patients with active, refractory Crohn’s disease indicate that rapid improvement in endoscopic findings was seen with single infusions of intravenous infliximab 3 to 20 mg/kg. Significant reductions from baseline in histology scores were also seen in recipients of infliximab 5 to 20 mg/kg, but not in placebo recipients, involved in a double-blind, randomised, 4-week trial (n = 30).
The efficacy of intravenous infliximab in patients with enterocutaneous abdominal or perianal fistulae was shown in a double-blind, randomised study in which 94 such patients received infliximab 5 or 10 mg/kg or placebo at weeks 0,2 and 6. Significantly more infliximab 5 and 10 mg/kg recipients (68 and 56%, respectively), compared with placebo recipients (26%), experienced a ≥50% reduction from baseline in the number of draining fistulae at ≥2 consecutive study visits (the primary endpoint). Moreover, a clinical response (defined as the absence of any draining fistulae at ≥2 consecutive study visits) was achieved in significantly more infliximab 5 and 10 mg/kg recipients than placebo recipients (55 and 38 vs 13%, respectively).
The results of clinical practice studies involving patients with active or fistulising Crohn’s disease tended to mirror those obtained in clinical studies. Infliximab has also shown efficacy in paediatric patients with Crohn’s disease. In a double-blind, randomised study involving 12 patients aged between 11 and 17 years who had refractory Crohn’s disease and who received a single infusion of intravenous infliximab 1, 5 or 10 mg/kg, five patients achieved remission.
In Rheumatoid Arthritis
The efficacy of combination therapy with intravenous infliximab plus methotrexate has been shown in two large (n = 428 and 101), double-blind, randomised studies involving patients with active rheumatoid arthritis who had not responded to prior methotrexate therapy. In the larger of these trials [the Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT) study] patients received intravenous infliximab 3 or 10 mg/kg or placebo at weeks 0, 2 and 6 and every 4 or 8 weeks subsequently. All patients also received methotrexate (median dosage 15 mg/week). After 30 weeks’ treatment, American College of Rheumatology (ACR) 20% (50 to 58 vs 20%), 50% (26 to 31 vs 5%) and 70% (8 to 18 vs 0%) response rates were significantly higher in infliximab plus methotrexate, compared with methotrexate plus placebo, recipients. Similarly, ACR 20% (42 to 59 vs 17%), 50% (21 to 39 vs 8%) and 70% (10 to 25 vs 2%) response rates remained significantly higher in infliximab plus methotrexate, compared with methotrexate plus placebo, recipients after 54 weeks’ treatment. Moreover, ACR 20% response rates were maintained after 102 weeks’ treatment (39.5 to 48.3 vs 15.9%). Significantly greater improvements in individual disease parameters (swollen and tender joint counts and C-reactive protein level) were also seen in infliximab plus methotrexate, compared with methotrexate plus placebo, recipients. Importantly, after 54 weeks’ treatment, infliximab plus methotrexate was associated with significantly less radiographic progression than methotrexate plus placebo [as assessed by changes in modified Sharp total (−0.7 to +1.6 vs +7), erosion (−0.7 to +0.3 vs +4) and joint space narrowing (0 to +1.1 vs +2.9) scores]. In the smaller double-blind, randomised study, patients received intravenous infliximab 1,3 or 10 mg/kg, either alone or in combination with methotrexate, at weeks 0, 2, 6, 10 and 14. Compared with methotrexate plus placebo, the median duration of response was significantly longer in recipients of infliximab 1 mg/kg plus methotrexate, infliximab 3 mg/kg with or without methotrexate or infliximab 10 mg/kg with or without methotrexate (0 vs 16.5, 16.5, 17.2, >18.1 and 10.4 weeks).
In addition, results from a large noncomparative study (n = 235) showed that symptomatic improvement was seen within 48 hours of infliximab administration in patients with active rheumatoid arthritis who had not responded adequately to methotrexate therapy.
The results of two noncomparative studies (n = 31 and 61 evaluable patients) showed that leflunomide may be an alternative to methotrexate for use in combination with infliximab in rheumatoid arthritis. In one of the studies, tender and swollen joint counts were reduced by 45 and 55%, respectively, and the mean prednisone dosage was reduced from 7.5 to 5 mg/day.
In Other Indications
Infliximab therapy has shown efficacy in indications other than Crohn’s disease and rheumatoid arthritis (e.g. ulcerative colitis, juvenile chronic arthritis, psoriatic arthritis, ankylosing spondylitis and adult-onset Still’s disease). However, to date, most of these data are obtained from small comparative or noncomparative trials.
Health-Related Quality of Life and Cost Considerations
In Crohn’s Disease
After 4 weeks’ follow-up, significantly greater improvements from baseline in Inflammatory Bowel Disease Questionnaire scores were seen in infliximab 5, 10 and 20 mg/kg recipients, compared with placebo recipients, in a double-blind, randomised study that enrolled 108 patients with active refractory Crohn’s disease. Moreover, significantly more infliximab than placebo recipients reported other quality-of-life benefits (e.g. with regard to energy levels, participation in leisure and sports activities and school and work attendance).
Infliximab therapy was associated with reductions in healthcare resource utilisation according to the results of a retrospective review. In addition, the results of a modelling study indicate that infliximab therapy may be cost saving in patients with active, refractory Crohn’s disease in certain clinical scenarios (e.g. if patients were to achieve remission similar to that obtained with surgery).
In Rheumatoid Arthritis
After 54 weeks’ follow-up in the ATTRACT study, recipients of infliximab plus methotrexate, compared with methotrexate plus placebo, had significantly greater improvements from baseline in Health Assessment Questionnaire scores, the physical component summary score from the Medical Outcomes Study Short-form Health Survey, the arthritis specific health index and patient global assessment of disease activity.
A modelling study using data from the ATTRACT study found infliximab to be associated with acceptable cost-effectiveness ratios in patients with rheumatoid arthritis. The results of a Spanish modelling study showed that treating patients with rheumatoid arthritis with infliximab plus methotrexate was more costly than treatment with leflunomide; this was mainly attributable to the higher acquisition cost of infliximab. In addition, the results of a Dutch modelling study showed that the total cost of infliximab plus methotrexate therapy was greater than that of etanercept therapy in rheumatoid arthritis; the higher cost was because infliximab was administered intravenously in an outpatient setting in combination with methotrexate.
Tolerability
Infliximab was generally well tolerated in clinical trials involving patients with Crohn’s disease or rheumatoid arthritis. Pooled results of clinical trials revealed that the most commonly occurring adverse events in patients with Crohn’s disease (n = 199) or rheumatoid arthritis (n = 555) who received infliximab were upper respiratory tract infection (16 and 26%, respectively), headache (23 and 22%, respectively), nausea (17 and 17%, respectively), coughing (5 and 13%, respectively), sinusitis (5 and 13%, respectively) and diarrhoea (3 and 13%, respectively). Approximately 6% of infliximab recipients discontinued therapy because of adverse events.
In clinical studies involving patients with Crohn’s disease or rheumatoid arthritis, treated infections occurred in 32% of infliximab recipients and 22% of placebo recipients. With regard to serious infections, during 6 months follow-up of patients with Crohn’s disease who received infliximab (n = 770) or placebo (n = 192), pneumonia occurred in 1.2 and 0.5% of infliximab and placebo recipients, respectively, cellulitis occurred in 0.5 and 0%, respectively, sepsis occurred in 0.5 and 1%, respectively, and abscess occurred in 0.1 and 0.5%, respectively.
Postmarketing surveillance has revealed a possible association between infliximab therapy and tuberculosis. As of June 30 2001, 84 cases of tuberculosis had been reported in infliximab recipients worldwide. It was thought that most of these cases represented reactivation of latent disease.
Infusion-related reactions have been reported in 19% of infliximab recipients and in 8% of placebo recipients involved in clinical trials. Reactions tended to be mild in nature and of transient duration; anaphylaxis has been reported infrequently. In a clinical study, delayed hypersensitivity reactions were reported in 25% of patients with Crohn’s disease who received retreatment with infliximab 2 to 4 years after initial infusion, although 90% of patients who experienced a delayed reaction received a liquid formulation of infliximab that is no longer in use.
The development of human antichimeric antibodies (HACA) has been reported in 13.4% of patients with Crohn’s disease receiving infliximab in clinical trials. Patients who develop HACA appear to be more likely to experience infusion-related reactions. In patients with rheumatoid arthritis, concomitant administration of methotrexate appears to potentiate immunological tolerance to infliximab. HACA developed in 53, 21 and 7% of patients receiving infliximab 1, 3 or 10 mg/kg, respectively, without methotrexate, and in 15, 7 and 0% of patients receiving infliximab 1, 3 or 10 mg/kg, respectively, plus methotrexate. The development of antinuclear antibodies and antibodies against double-stranded DNA has also been reported in patients with Crohn’s disease or rheumatoid arthritis who received infliximab in clinical trials.
Long-term follow-up (3 years) of patients with Crohn’s disease or rheumatoid arthritis involved in clinical trials revealed the development of malignancy in 14 out of 770 infliximab recipients and in 1 out of 192 placebo recipients.
Preliminary reports indicate higher incidences of death and hospitalisation for worsening heart failure in infliximab recipients (especially those receiving the 10 mg/kg dose) than placebo recipients in a trial involving 150 patients with New York Heart Association class III to IV congestive heart failure who received three infusions of infliximab 5 or 10 mg/kg or placebo over 6 weeks. Seven out of 101 infliximab recipients died, compared with none of the 49 placebo recipients.
Infliximab and etanercept have both been associated with neurological adverse events (rare cases of optic neuritis, seizures and central nervous system demyelinating disorders, including multiple sclerosis).
Dosage and Administration
In Crohn’s disease, infliximab is indicated for use in patients with active disease (moderate to severe disease in the US and severe disease in the European Union) who have not responded to conventional treatment and in patients with fistulising disease (in the European Union patients with fistulae must be refractory to conventional therapy). The recommended dosage in active Crohn’s disease is a single intravenous infusion of 5 mg/kg; it is recommended that patients with fistulising Crohn’s disease receive intravenous infusions of infliximab 5 mg/kg at weeks 0, 2 and 6.
With regard to rheumatoid arthritis, in the US, infliximab is approved for use in combination with methotrexate to reduce symptoms and signs, inhibit the progression of structural damage and improve physical function in patients with active moderate-to-severe disease who have not had an adequate response to methotrexate. In the European Union, infliximab is approved for use in combination with methotrexate to reduce symptoms and signs in patients with active disease who have had an inadequate response to treatment with disease-modifying antirheumatic drugs (including methotrexate). Intravenous infusions of infliximab 3 mg/kg should be administered at weeks 0, 2 and 6 and every 8 weeks thereafter.
The US manufacturers of infliximab recommend that patients should undergo tuberculin skin testing prior to starting treatment with infliximab to help exclude the presence of latent infection. Patients found to have latent tuberculosis should commence antitubercular treatment before they start infliximab therapy. In the European Union the use of infliximab is contraindicated in patients with tuberculosis and all patients must be evaluated for active and latent tuberculosis prior to starting the drug.
Infliximab should not be given to patients with clinically important, active infections or initiated in patients with congestive heart failure. In Europe infliximab is contraindicated in patients with moderate or severe heart failure. Infliximab should be administered with caution to patients with chronic infection or a history of recurrent infection and to patients with central nervous system demyelinating disorders that are pre-existing or of recent onset. Infliximab should be discontinued in patients with congestive heart failure who experience a worsening of their condition, patients who develop serious infections, patients who develop severe infusion-related reactions and patients who develop symptoms suggestive of a lupus-like syndrome. Patients should be monitored for the presence of infection both during and after infliximab therapy and the cardiovascular status of patients with congestive heart failure who continue to receive infliximab therapy should be monitored.
Similar content being viewed by others
References
Garnett WR, Yunker N. Treatment of Crohn’s disease with infliximab. Am J Health Syst Pharm 2001 Feb 15; 58(4): 307–16
Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. Biodrugs 2001; 15(6): 379–93
Van Deventer SJH. Immunotherapy of Crohn’s disease. Scand J Immunol 2000 Jan; 51(1): 18–22
American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39(5): 713–22
Brennan FM, Maini RN, Feldmann M, et al. TNFα — a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293–8
Feldmann M, Maini RN. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163–96
Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn’s disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14(1): 47–51
Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30(16): 1443–53
Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. Biodrugs 1998 Nov; 10: 397–422
Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59
Arend WP. Cytokine inhibition in the treatment of rheumatic and inflammatory diseases. Jpn J Rheumatol 1998; 8(4): 333–45
Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999 May; 5(2): 119–33
Lichtenstein GR. Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment. Curr Opin Gastroenterol 2000; 16(1): 83–8
Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397–440
Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283–350
Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001 Mar 22; 344(12): 907–16
Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92(12): 5S–11S
Agnholt J, Kaltoft K. Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn’s disease. Cytokine 2001 Aug; 15(4): 212–22
Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7(3): 251–9
Bell SJ, Kamm MA. Review article: the clinical role of anti-TNFα antibody treatment in Crohn’s disease. Aliment Pharmacol Ther 2000 May; 14(5): 501–14
Arnott IDR, Shand A, Ghosh S. Administration of infliximab in Crohn’s disease does not deplete complement components C3 and C4 [letter]. Am J Gastroenterol 2000 Nov; 95(11): 3326–7
Hove T, van Deventer SJH. Anti-TNF antibody CA2 induces apoptosis in CD3/CD28 stimulated Jurkat cells; a potent immunomodulatory mechanism [abstract]. Gastroenterology 1999 Apr; 116 (Pt 2)(4): 739
Van Deventer SJH. Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology 2001 Nov; 121(5): 1242–6
Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001 Nov; 121(5): 1145–57
Tak PP, Taylor C, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077–81
Lorenz H-M, Grünke A, Hieronymus T, et al. In vivo blockade of tumor necrosis factor-α in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol 2000 Feb; 27: 304–10
Shealy D, Mace K, DeWoody K, et al. Reduction in serum VEGF and sICAM-1 are associated with clinical response to anti-TNF therapy in patients with severe Crohn’s disease [abstract]. Gastroenterology 1997; 112(4): A1090
Schlüter UG, Ledeboer M, Arndt JW, et al. Very rapid anti-inflammatory effect of anti-TNF-A (Remicade™) in Crohn’s disease as assesssed by 99MTC-WBC-scintigraphy [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): A568
Radema SA, van Dullemen JM, Tytgat GNJ, et al. Decreased production of chemokines in patients with Crohns disease after anti-TNF therapy [abstract]. Clin Immunol Immunopathol 1995; 76(Pt 2): S45
Paleolog E, Young S, McClosky RV, et al. Angiogenesis as a therapeutic target in rheumatoid arthritis: serum vascular endothelial growth factor is decreased by anti-TNFα therapy [abstract]. Clin Exp Rheumatol 1998; 16(2): 232
Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 1997; 159: 6276–82
Ulfgren A-K, Andersson U, Engström M, et al. Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis. Arthritis Rheum 2000 Nov; 43(11): 2391–6
Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000 Jan; 43(1): 38–47
Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short tem cellular and molecular effects. J Immunol 1996; 156: 1646–53
Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999 Aug 1; 163(3): 1521–8
Ohshima S, Saeki Y, Mima T, et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNFα antibody therapy. J Clin Immunol 1999 Sep; 19(No. 5): 305–13
Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn’s disease anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–35
Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 2001 Apr; 15(4): 463–73
Baert FJ, D’Haens GR, Peeters M, et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999 Jan; 116(1): 22–8
Maurice MM, van der Graaff WL, Leow A, et al. Treatment with monoclonal antibody anti-tumor necrosis factor α antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999 Oct; 42(10): 2166–73
Paleolog EM, Hunt M, Elliot MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082–91
van Dullemen HM, Wolbink GJ, Wever PC, et al. Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn’s disease: relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans and in active Crohn’s disease. Scand J Gastroenterol 1998 Oct; 33: 1094–8
Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997 Jun; 36: 643–50
Perkins DJ, St Clair EW, Misukonis MA, et al. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor α monoclonal antibody (cA2). Arthritis Rheum 1998 Dec; 41(12): 2205–10
Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994 Aug; 94: 749–60
Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritis. J Clin Mol Pathol 1997; 50: 225–33
Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000 Apr; 27(4): 841–50
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552–63
Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al. Arthritis Rheum 1999 Aug; 42(8): 1779
Maini RN, Feldmann M, Schaible T. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? [letter, reply]. Arthritis Rheum 1999 Aug; 42(8): 1779–81
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 Dec 4; 354(9194): 1932–9
Centocor I. Remicade® (infliximab) recombinant for IV injection prescribing information [online]. Available from URL: http://www.centocor.com [Accessed 2002 Mar 8]
Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999 Oct; 117(4): 761–9
Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001 Jul; 96(7): 1977–97
European Agency for the Evaluation of Medicinal Products. Summary of product characteristics for infliximab [online]. Available from URL: http://www.emea.eu.int [Accessed 2002 Mar 8]
Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997; 337: 1029–35
D’Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999 May; 116(5): 1029–34
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999 May 6; 340(18): 1398–405
Rutgeerts P, Colombel JF, Schreiber S, et al. Treatment of Crohn’s disease (CD): response to Remicade(R) (infliximab) in the ACCENT I trial through week 54 [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S303
Asakura H, Yao T, Matsui T, et al. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-α for Crohn’s disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001 Jul; 16(7): 763–9
McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease [abstract]. Gastroenterology 1996 Apr; 110: 962
Schreiber S, Kuehbacher T, Mascheretti S, et al. Clinical efficacy of treatment with infliximab in a German multicenter, prospective, open-label trial in refractory Crohn’s disease [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Part 1): A568
Toy LS, Marion JF, Scherl EJ, et al. Infliximab therapy for Crohn’s disease fistulae: number of infusions required for response and time to relapse [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): 569
Ertan A, Darmadi DH. Inflixmab (anti-TNF-α antibody) in treatment of rectovaginal fistulas with Crohn’s disease [abstract]. Am J Gastroenterol 1999 Sep; 94: 2670
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s Disease Activity Index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 439–44
Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Gut 1989; 30: 983–9
Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20(1): 27–32
Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000 Dec; 95(12): 3490–7
Shah S, Fefferman D, Farrell RJ, et al. Efficacy and safety of infliximab in 221 Crohn’s disease patients. Am J Gastroenterol 2000 Sep; 95: 2640–1
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: first anniversary clinical experience. Am J Gastroenterol 2000 Dec; 95(12): 3469–77
Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001 Mar; 96(3): 722–9
Munkholm P, Dahlerup JF, Buntzen S, et al. Infliximab in Danish Crohn’s disease patients [abstract]. Gut 2000 Dec; 47(Suppl. III): A245
Mortimore M, Gibson PR, Selby WS, et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Infliximab User Group. Intern Med J 2001 Apr; 31(3): 146–50
Chusid BG, Korelitz BI, Blank A, et al. Intravenous Remicade outpatient treatment of Crohn’s disease: a personal experience [abstract]. Am J Gastroenterol 2000 Sep; 95: 2531
McCabe RP, Schwartz RM, Bebeau V, et al. Treatment of Crohn’s disease with infliximab — an initial community practice experience [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): A567
Arnott IDR, McDonald D, Williams A, et al. Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther 2001 Oct; 15(10): 1639–46
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980 Mar 8; 1: 514
Baldassano R, Vasiliauskis E, Braegger CP, et al. A multicenter study of infliximab (anti-TNFα antibody) in the treatment of children with active Crohn’s disease [abstract]. Gastroenterology 1999 Apr 2; 116: 665
Vasiliauskas EA, Schaffer S, Dezenberg CV, et al. Collaborative experience of open-label infliximab in refractory pediatric Crohn’s disease [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): A178
Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000 Nov; 95(11): 3189–94
Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000 Aug; 137(2): 192–6
Serrano M-S, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001 Jul-2001 31; 35: 823–8
Vasiliauskas E, Targan S, Sands B, et al. Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohn’s disease [abstract]. Gastroenterology 1999 Apr; 116(Pt 2): 837
Nikolaus S, Raedler A, Kiihbacker T, et al. Mechanisms in failure of infliximab for Crohn’s disease. Lancet 2000 Oct 28; 356(9240): 1475–9
Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001 May; 120(6): 1347–55
Lichtenstein GR, Stein R, Lewis JD, et al. Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn’s disease [abstract]. Am J Gastroenterol 1999 Sep; 94: 2676
D’Haens GR, Aerden I, van Hogezand R, et al. Duration of response following cessation of infliximab therapy for active or fistulizing Crohn’s disease [abstract]. Gastroenterology 1999 Apr; 116(Pt 2): 696
Rutgeerts P, Mayer L, Schreiber S, et al. Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn’s disease [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S302
Hanauer S, Schreiber S, Bao W, et al. ACCENT I trial: infliximab response rates over 30 weeks [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S302
Lichtenstein GR, Bao W, Keenan G, et al. Infliximab (Remicade) treatment allows Crohns disease to reduce or discontinue concomitant corticosteroid use [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S302
Mayer L, Han C, Bala M, et al. Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohns disease (CD) [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): 303
Kam LY, Vasiliauskas EA, Abreu MT, et al. Attenuation of response to multiple retreatment infliximab infusions for active Crohn’s disease (CD): potential factors that minimize decreased response [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): 655
Rawlins M, Gelfand M, Kozarek R, et al. Does coadministration of immunosuppressive agents alter response to infliximab in Crohn’s disease? [abstract]. Am J Gastroenterol 2000 Sep; 95: 2548–9
Onken JE, Sands B, Hogezand R, et al. Consistent treatment benefit with infliximab in patients with fistulizing Crohn’s disease [abstract]. Gastroenterology 1999 Apr 2; 116: 788
Pittman R, Toy LS, Kornbluth A, et al. Pretreatment with 6-mercaptopurine/azathioprine prolongs clinical response time in Crohn’s disease (CD) patients with fistulizing disease (FD) treated with inflixmab [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): 788
Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 2001 Mar; 96: 635–43
Sapienza MS, Cohen S, DiMarino AJ, et al. Improvement of pyoderma gangrenosum after infliximab treatment for fistulizing Crohn’s disease [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S307
Tan M-H, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor α monoclonal antibody. Arch Dermatol 2001 Jul; 137(7): 930–3
van der Schaar P, Wensveen C, Bavink JNB, et al. Treatment with anti-TNF alpha (Remicade) for pyoderma gangrenosum in Crohn’s colitis — case report [abstract]. Gut 2000 Dec; 47(Suppl. III): A245
Van den Bosch F, Kruithof E, De Vos M, et al. Crohn’s disease with spondyloarthropathy: effect of TNF-α blockade (infliximab) on articular symptoms. Ann Rheum Dis 2000 Jul; 59(Suppl. 1): 201
Ellman MH, Hanauer S, Sitrin M, et al. Crohn’s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 2001 Apr; 7: 67–71
Heller T, James SP, Drachenberg C, et al. Treatment of severe esophageal Crohn’s disease with infliximab. Inflamm Bowel Dis 1999 Nov; 5(4): 279–82
Fefferman DS, Shah SA, Alsahlil M, et al. Successful treatment of refractory esophageal Crohn’s disease with infliximab [letter]. Dig Dis Sci 2001 Aug; 46(8): 1733–5
Mahadevan U, Sandborn WJ. Infliximab for the treatment of orofacial Crohn’s disease. Inflamm Bowel Dis 2001 Feb; 7(1): 38–42
Hunt SA, Bayless TM, Harris ML. Extensive dermatologic complications of Crohn’s disease: response to Remicade [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): A566
Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001 May; 7(2): 83–8
Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001 May; 7Suppl. 1: S30–3
Su CG, Salzberg B, Lewis J, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S310
Mamula P, Markowitz JA, Hurd LB, et al. Infliximab, novel therapy for pediatric ulcerative colitis [abstract]. 14th Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition; 2001 Oct 25–28; Orlando (FL). Available from URL: http://www.abstracts-on-line.com [Accessed 2002 Jan 2]
Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factorα (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10
Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factorα. Arthritis Rheum 1993; 36: 1681–90
Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factorα (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7
Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 Nov 30; 343(22): 1594–602
Antoni CE, Dechant C, Haentzschel H, et al. Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis (RA) despite methotrexate therapy: a German open label trial [abstract]. Arthritis Rheum 2001 Sep; 44(Suppl. 9): S84
Fantini F, Sinigaglia L, Zeni S, et al. Short-term treatment with monoclonal antitumor necrosis factor-α antibody in refractory long-standing rheumatoid arthritis [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): 227
Shergy W, Isern R, Cooley D, et al. Infliximab (Remicade®) ameliorates clinical signs and symptoms of rheumatoid arthritis within 48 hours: results of the PROMPT study [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): 227
Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6): 727–35
Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33(4): 477–84
van der Heijde DMFM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatology 1996; 10: 435–53
Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide (LEF) in combination with infliximab (INF) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001 Sep; 44(Suppl. 9): S84
Patel S, Bergen W, Kraemer A, et al. Effiacy and safety of Remicade(Rm) (infliximab) plus Arava(TM) (leflunomide) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001 Sep; 44(Suppl. 9): 84
Lipsky P, van der Heijde D, St Clair W, et al. 102-Wk clinical and radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in pts with active RA despite MTX [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): 269
van der Heijde DM, Landewe RB, Lipsky PE, et al. Radiological progression rate at baseline predicts treatment differences: results from the ATTRACT trial [abstract]. Arthritis Rheum 2001 Sep; 44(Suppl. 9): S80
Emery P, Maini RN, Lipsky PE, et al. Infliximab plus methotrexate prevents structural damage, reduces signs and symptoms and improves disability in patients with active early rheumatoid arthritis [abstract]. Ann Rheum Dis 2000 Jul; 59(Suppl. 1): 48
Antoni C, Maini R, Breedveld F, et al. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (ATTRACT) with an anti-TNFα monoklonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate [abstract]. Ann Rheum Dis 1999 Jun 6, 217
van der Heijde DMFM, Emery P, Lipsky PE, et al. Consistent improvement in radiographic joint damage in patients with active rheumatoid arthritis treated with infliximab along with methotrexate [abstract]. Ann Rheum Dis 2000 Jul; 59(Suppl. 1): 161
Lahdenne P, Honkanen V. Infliximab vs. etanercept in the treatment of severe juvenile chronic arthritis [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): 381
Gerloni V, Pontikaki I, Desiati F, et al. Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile idiopathic (chronic) arthritis treated with monoclonal anti-tumor necrosis factor-α antibody (infliximab) [abstract]. J Rheumatol 2001 Jul; 28(Suppl. 63): 67
Bolce RJ, Thompson J, Stevens MP, et al. Treatment of psoriatic arthritis with infliximab in a small office-based rheumatology practice [abstract]. Arthritis Rheum 2001; 44 (Suppl.): S121
Antoni C, Dechant C, Lorenz HM, et al. Successful treatment of psoriatic arthritis with infliximab in a MRI controlled study [abstract]. Ann Rheum Dis 2000 Jul; 59(Suppl. 1): 200
Brockbank JE, Lapp V, Gladman DD, et al. Infliximab therapy in 15 patients with psoriatic arthritis [abstract]. J Rheumatol 2001 Jul; 28(Suppl. 63): 62
Brandt J, Listing J, Alten R, et al. Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNFα antibody infliximab in a placebo-controlled multicenter trial [abstract]. Arthritis Rheum 2001; 44(Suppl.): S89
Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000 Jun; 43(6): 1346–52
Brandt J, Haibel H, Reddig J, et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002 Jan; 29(1): 118–22
Boeger CA, Wittwer H, Schattenkirchner M, et al. Treatment of ankylosing spondylitis with infliximab [letter]. Ann Rheum Dis 2001 Dec; 60(12): 1159–60
Kaiser MJ, Sany J. Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies. two case reports [letter]. Joint Bone Spine 2001 Dec; 68(6): 525–7
Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 2001; 60(Suppl. 3): 55–7
Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 2001 May-2001 30; 19(3): 329–32
Feagan B, Han C, Bala M, et al. Infliximab (Remicade) treatment results in rapid quality of life improvement in patients with Crohn’s disease [abstract]. Am J Gastroenterol 2001 Sep; 96(Suppl. 9): S303
DeWoody KL, Bala MV, Schaible TF. Infliximab improves quality of life in Crohn’s disease patients [abstract]. Am J Gastroenterol 1999 Sep; 94: 2670
Kavanaugh A, Lipsky P, Furst D, et al. Infliximab improves long-term quality of life and functional status in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): S147
Guyatt GH, Mitchell A, Irvine EJ, et al. Anew measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804–10
Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287–96
Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1908 Feb; 23(2): 137–45
Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survery (SF-36). Med Care 1992 Jun; 30(6): 473–83
Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource utilization in patients with Crohn’s disease [abstract]. Am J Gastroenterol 2000 Sep; 95(9): 2499
Annemans L, Moeremans K, Rutgeerts P, et al. Analysis of the long-term costs, savings and effects generated by infliximab to normalize quality of life in patients with Crohn’s disease [abstract]. Value Health 2001 Mar-2001 30; 4: 127
Patterson D, Kozarek R, Gelfand M, et al. Infliximab: outcomes and costs in refractory Crohn’s disease [abstract]. Am J Gastroenterol 1999 Sep; 94: 2682
Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001 Jun; 120(7): 1640–56
Wong JB, Loftus Jr EV, Sandborn WJ, et al. Estimating the cost-effectiveness of infliximab for Crohn’s disease [abstract]. Gastroenterology 1999 Apr; 116(Pt 2): A104–105
Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): S144
Kavanaugh A, Patel KK, Bala M, et al. Cost effectiveness of infliximab in rheumatoid arthritis [abstract]. Arthritis Rheum 2000 Sep; 43(Suppl.): 144
Rubio-Terrés C, Dominguez-Gil A. Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with Leflunomide in comparison with the combination of infliximab and methotrexate. J Drug Assess 2001; 4(Pt 1): 39–54
Nuijten MJC, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19(10): 1051–64
Hanauer SB, Schaible TF, DeWoody KL, et al. Long-term follow-up of patients treated with infliximab (anti-TNFα antibody) in clinical trials [abstract]. Gastroenterology 2000 Apr; 118(Suppl. 2. Pt 1): 566
Isern RA, Sanders C, Hughes G, et al. Safety and tolerability of a rapid infusion of Remicade (infliximab) in the treatment of rheumatoid arthritis [abstract]. Annual European Congress of Rheumatology; 2001 Jun 13–16; Prague. Available from URL: http://www.eular.org [Accessed 2002 Jan 2]
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001 Oct 21; 345(15): 1098–104
Centocor Inc. Important drug warning [letter]. Available from URL: http://www.centocor.com [Accessed 2001 Dec 3]
Hanauer SB, Rutgeerts PJ, D’Haens G, et al. Delayed hypersensitivity to infliximab (Remicaide®) re-infusion after a 2–4 year interval without treatment [abstract]. Gastroenterology 1999 Apr; 116(Pt 2): A731
Lankarani KB. Mortality associated with infliximab [letter]. J Clin Gastroenterol 2001 Sep; 33(3): 255–6
Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case [letter]. Am J Gastroenterol 2000 Sep; 95(9): 2395–6
Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to doublestranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000 Nov; 43(11): 2383–90
Food and Drug Administration. Remicade (infliximab) — clinical alert: congestive heart failure. Available from URL: http://www.fda.gov/medwatch [Accessed 2001 Oct 29]
Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44(12): 2862–9
Antoni CE, Furst D, Manger B, et al. Outcome of pregnancy in women receiving Remicade® (infliximab) for the treatment of Crohn’s disease or rheumatoid arthritis [abstract]. Arthritis Rheum 2001 Sep; 44(Suppl. 9): S152
Hanauer SB, Cohen RD, Becker RV 3rd, et al. Advances in the management of Crohn’s disease: economic and clinical potential of infliximab. Clin Ther 1998 Sep-1998 31; 20(5): 1009–28
Yelin E, Wanke LA. An asessment of the annual and long-term direct costs of rheumatoid arthritis. Arthritis and Rheumatism 1999 Jun; 42(6): 1209–18
Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23(Suppl. 44): 47–51
Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 2001 Oct; 15(10): 1515–25
Sandborn WJ. Steroid-dependent Crohn’s disease. Can J Gastroenterol 2000 Sep; 14Suppl. C: 17C–22C
Panaccione R. Infliximab for the treatment of Crohn’s disease: review and indications for clinical use in Canada. Can J Gastroenterol 2001 Jun; 15(6): 371–5
D’Haens G. Infliximab (Remicade): the magic bullet for Crohn’s disease? Dig Liver Dis 2000 Nov; 32(8): 653–6
Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003. Int J Colorectal Dis 2001 Feb; 16(1): 1–11
Fedorak RN. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn’s disease. Can J Gastroenterol 2001 Jun; 15(6): 367–70
Griffiths AM. Crohn’s disease in children and adolescents: what are the treatment options? Drugs Today 1999; 35(Suppl. A): 5–16
Walker-Smith JA. Chronic inflammatory bowel disease in children: a complex problem in management. Postgrad Med J 2000; 76(898): 469–72
Gabriel SE, Coyle D, Moreland LW. Clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001; 19(7): 715–28
Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001 Apr 17; 134(8): 695–706
Pope RM. Rheumatoid arthritis: pathogenesis and early recognition. Am J Med 1996 Feb 26; 100(Suppl. 2A): 3S–9S
Guedes C, Dumont-Fischer D, Leichter-Nakache S, et al. Mortality in rheumatoid arthritis. Rev Rhum — English Edition: Joint, Bone, Spine Diseases 1999: 492–8 1999 Oct; 66(10): 492–8
Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000 Jan; 43(1): 14–21
Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1423–30
Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57: 945–66
Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 Nov 30; 343(22): 1586–93
Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340(4): 253–9
Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337(3): 141–7
Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: arandomized, controlled trial. Ann Intern Med 1999 Mar 16; 130(6): 478–86
Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 Nov; 121: 1088–94
Immunex Corporation. Enbrel® (etanercept) prescribing information. Available from URL: http://www.immunex.com [Accessed 2001 Sep 10]
European Agency for the Evaluation of Medicinal Products. Summary of product characteristics for etanercept. Available from URL: http://www.emea.eu.int [Accessed 2001 Oct 1]
Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001 Jun; 40(6): 699–702
Working Party of the British Society for Rheumatology. Guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis. Available from URL: http://www.rheumatology.org.uk [Accessed 2001 Sep 5]
Etanercept and infliximab for rheumatoid arthritis. Drug Ther Bull 2001 Jul; 39 (7): 49–52
Gallup E. Coverage inequalities of new therapies for rheumatoid arthritis in a managed care setting. Manag Care Interface 2001 Jul; 14(7): 52–69
Amgen Inc.. FDA approves Kineret™ for the treatment of rheumatoid arthritis. Available from URL: http://www.amgen.com [Accessed 2001 Dec 3]
Amgen Inc.. Kineret™ (anakinra) prescribing information. Available from URL: http://www.amgen.com [Accessed} 2001 Dec 3]
Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000 May; 43(5): 1001–9
Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998 Dec; 41(12): 2196–204
American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996 May; 39: 723–31
Steinhart H. Maintenance therapy in Crohn’s disease. Can J Gastroenterol 2000 Sep; 14Suppl. C: 23C–8C
Sandborn WJ. Transcending conventional therapies: the role of biologic and other novel therapies. Inflamm Bowel Dis 2001 May; 7Suppl. 1: S9–16
Sandborn WJ. Strategies targeting tumor necrosis factor in Crohn’s disease. Acta Gastroenterol Belg 2001 Apr-2001 30; 64(2): 170–2
Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy — a critical review. Can J Gastroenterol 2001 Jun; 15(6): 376–84
Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000 Sep; 14Suppl. C: 29C–32C
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keating, G.M., Perry, C.M. Infliximab. BioDrugs 16, 111–148 (2002). https://doi.org/10.2165/00063030-200216020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-200216020-00005